EMEA Has Designated Orphan Drug Status To The Developmental Anti-Cancer Drug AZD2281

The European Medicines Agency (EMEA) has designated orphan drug status to the developmental anti-cancer drug AZD2281, a small molecule PARP (poly[ADP-ribose] polymerase) inhibitor, for treating women with ovarian cancer. Data from a Phase I trial was presented at a major oncology meeting (American Society of Clinical Oncology) in June this year, where strong evidence of tumour response in patients with hereditary ovarian cancer was reported. [click link for full article]

More: continued here

Filed under: Cervical Cancer on December 20th, 2007